NASDAQ · VTGN
Vistagen Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VTGN: Nov 12, 2026
Vistagen Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.37. The reported EPS for the same quarter last year was $-0.54.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Dec 2026 | $-0.36 | $-0.36 | $-0.36 | 1 |
| Mar 2027 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Jun 2027 | $0.03 | $0.03 | $0.03 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks- RTTNews · Sep 25, 2:07 AM EDTSRX Global Liquidates 2 Portfolio Investments, Adds Onconetix Ahead Of Realbotix Deal(RTTNews) – SRX Global Inc. (SRXH), an AI-driven investment platform, provided an update on the liquidation of two portfolio investments and announced a new investment in Onconetix, Inc. (ONCO).
- RTTNews · Sep 24, 10:14 AM EDTVistagen Reports Positive Findings Supporting Fasedienol's Potential In Very Severe SAD(RTTNews) – Vistagen (VTGN), a late clinical-stage biopharmaceutical company developing a new class of intranasal product candidates known as pherines, reported positive exploratory findings supporting the potential of Fasedienol in individuals with very severe social anxiety dis
- RTTNews · Sep 22, 11:10 AM EDTVistagen Reports Preliminary Data From Fasedienol Phase 3 Extension Study; Stock Up(RTTNews) – Vistagen Therapeutics (VTGN) announced preliminary data from the open-label extension (OLE) portion of its PALISADE-4 Phase 3 study evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder.
- RTTNews · Aug 14, 12:36 PM EDTVistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path(RTTNews) – Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update.
- RTTNews · Aug 4, 5:51 AM EDTSRX Global Acquires Stake In Vistagen Therapeutics; Shares Edge Higher In Pre-Market(RTTNews) – SRX Global Inc. (SRXH), an AI-enabled investment platform, announced it has acquired a stake in Vistagen Therapeutics, Inc. (VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience. Vistagen is pioneering nose-to-brain neurocircuitry with a new
- RTTNews · Jul 2, 10:09 AM EDTWeekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal(RTTNews) – The holiday-shortened week delivered no shortage of action for the biotech sector, with a mix of FDA, China, Canada, and EU approvals, acquisitions, and positive clinical readouts, alongside regulatory rejections, program discontinuations, and trial goal misses.
- RTTNews · Jun 30, 11:44 AM EDTVistagen Plunges After Disappointing Phase 3 PALISADE-4 Trial; Stock Hits All-Time Low(RTTNews) – Shares of Vistagen Therapeutics Inc. (VTGN) are down over 70% on Tuesday, following disappointing results from its PALISADE-4 trial.
- Zacks · Jun 3, 5:15 PM EDTVeeva Systems (VEEV) Q1 Earnings and Revenues Surpass EstimatesVeeva (VEEV) delivered earnings and revenue surprises of +5.10% and +2.99%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 28, 5:40 PM EDTHealthEquity (HQY) Q1 Earnings and Revenues Top EstimatesHealthEquity (HQY) delivered earnings and revenue surprises of +11.57% and +0.06%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 20, 8:15 AM EDTRoivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue EstimatesMontes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -41.18% and -8.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 18, 9:00 AM EDTCompugen (CGEN) Reports Q1 Loss, Lags Revenue EstimatesCompugen (CGEN) delivered earnings and revenue surprises of -9.14% and -16.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · May 12, 8:16 AM EDTVistagen Reports Positive Preliminary Phase 3 Data For Fasedienol In Social Anxiety Disorder(RTTNews) – VistaGen Therapeutics Inc (VTGN) on Tuesday announced preliminary positive data from the ongoing open-label extension portion of its Phase 3 PALISADE-3 study evaluating fasedienol for the acute treatment of social anxiety disorder.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Vistagen Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.